| Literature DB >> 33801092 |
Jérôme Grondin1,2, Pierre Menu1,2,3,4, Benoit Métayer5, Vincent Crenn6,7, Marc Dauty1,2,3,4, Alban Fouasson-Chailloux1,2,3,4.
Abstract
Periprosthetic joint infections (PJI) occur in 0.5 to 2.8% of total knee arthroplasties (TKA) and expose them to an increase of morbidity and mortality. TKA are mainly performed after failure of non-surgical management of knee osteoarthritis, which frequently includes intra-articular injections of corticosteroids or hyaluronic acid. Concerning the potential impact of intra-articular injections on TKA infection, literature provides a low level of evidence because of the retrospective design of the studies and their contradictory results. In this prospective cohort study, we included patients after a total knee arthroplasty, at the time of their admission in a rehabilitation center, and we excluded patients with any prior knee surgery. 304 patients were included. Mean follow-up was 24.9 months, and incidence proportion of PJI was 2.6%. After multivariate logistic regression, male was the only significant risk factor of PJI (OR = 19.6; p = 0.006). The incidence of PJI did not differ between patients who received prior intra-articular injections and others, especially regarding injections in the last 6 months before surgery. The use of intra-articular injection remains a valid therapeutic option in the management of knee osteoarthritis, and a TKA could still be discussed.Entities:
Keywords: infection; intra-articular injection; knee; total knee arthroplasty
Year: 2021 PMID: 33801092 PMCID: PMC8004162 DOI: 10.3390/antibiotics10030330
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Flow-chart.
Demographic characteristics.
| Characteristics | Patients ( |
|---|---|
| Mean age, years ± SD | 71.8 ± 8.9 |
| [min–max] | [31–91] |
| Sex: | |
| -Female, | 220 (72.4) |
| -Male, | 84 (27.6) |
| Mean weight, kg ± SD | 82.0 ± 16.3 |
| [min–max] | [46–149] |
| Mean height, cm ± SD | 162.9 ± 9.3 |
| [min–max] | [136–190] |
| Mean BMI, kg/m2 ± SD | 30.9 ± 5.3 |
| [min–max] | [19.4–47.6] |
| Diabetes mellitus: | |
| -Type 1, | 7 (2.3) |
| -Type 2, | 43 (14.1) |
| -None, | 254 (83.6) |
| Smoking: | |
| -Active, | 14 (4.6) |
| -Cessation, | 49 (16.1) |
| -None, | 241 (79.3) |
| Alcoholism: | |
| -Active, | 23 (7.5) |
| -Cessation, | 5 (1.7) |
| -None, | 276 (90.8) |
| Mean ASA Score, mean ± SD | 2.3 ± 0.6 |
| [min–max] | [1–4] |
| Prior IA injection, | 207 (68.1) |
| -CS | 32 (15.5) |
| -HA | 101 (48.8) |
| -CS+HA | 51 (24.6) |
| -Unknown | 23 (11.1) |
| No prior IA injection, | 97 (31.9) |
SD: Standard-deviation; BMI: Body mass index; ASA: American society of anesthesiologists; IA: Intra-articular; CS: Corticosteroids; HA: Hyaluronic acid.
Cases of periprosthetic joint infections.
| Patients | Age | Sex | BMI | Diabetes | Smoking | Alcoholism | ASA | Infiltrations | Delay Surgery-PJI | Surgery | Bacteria | Antibiotic Therapy | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DTS | Medication |
| Type | Duration | |||||||||||
| 1 | 73 | M | 32.3 | No | No | Yes | 1 | 14 m | CS | 1 | 11 d | Debridement, implant retention, replacement of exchangeable components | Methi-S Staph. aureus | Levofloxacin + | 12 w |
| 2 | 64 | F | 33.3 | Type 2 | No | No | 3 | - | - | 0 | 4 w | One-Stage Arthroplasty Exchange | Methi-S Staph. aureus | Levofloxacin + | 12 w |
| 3 | 88 | M | 20.4 | No | Former smoker | No | 2 | 1 m | HA | 9 | 5 w | One-Stage Arthroplasty Exchange | Methi-S Staph. aureus | Levofloxacin + | 12 w |
| 4 | 78 | F | 37.5 | No | No | No | 3 | - | - | 0 | 5 w | Debridement, implant retention, replacement of exchangeable components | Methi-S Staph. aureus | Levofloxacin + | 12 w |
| 5 | 85 | M | 28.7 | No | No | No | 3 | 4 m | CS | 3 | 4 w | Debridement, implant retention, replacement of exchangeable components | Methi-S Staph. aureus | Levofloxacin + | 12 w |
| 6 | 53 | M | 26.9 | No | No | No | 2 | 12 m | HA | unknown | 12 d | Debridement, implant retention, replacement of exchangeable components | Staph. capitis | Levofloxacin + | 8 w |
| 7 | 77 | M | 24.4 | No | Former smoker | No | 3 | 10 m | CS + HA | 7 | 5 m | Initially irrigation and debridment, then 4 months later 1-Stage Arthroplasty Exchange | Strep. oralis | Moxifloxacin + | 12 w |
| 8 | 74 | M | 29.4 | No | Current smoker | No | 3 | 4 m | CS + HA | 7 | 14 d | Debridement, implant retention, replacement of exchangeable components | Methi-R Staph. aureus | Cotrimoxazole + fusidic acid, | 12 w |
F: Female; M: Male; BMI: Body mass index; ASA: American society of anesthesiologists; DTS: Delay to surgery; m: Months; d: Days; w: Weeks; CS: Corticosteroids; HA: Hyaluronic acid; PJI: Periprosthetic Joint Infections; Methi-S: Methicillin sensitive; Methi-R: Methicillin resistant, Staph.: Staphylococcus; Strep.: Streptococcus.
Univariate logistic regression according to patients’ characteristics.
| Independent Variables | Odds-Ratio | CI 95% |
|
|---|---|---|---|
| Age | 1.03 | 0.94–1.12 | 0.48 |
| Sex | 0.05 | 0.006–0.41 | 0.005 |
| BMI | 0.93 | 0.8–1.08 | 0.35 |
| Smoking | 2.36 | 0.54–10.1 | 0.24 |
| Diabetes mellitus | 0.72 | 0.08–5.98 | 0.76 |
| Alcoholism | 1.77 | 0.2–15.1 | 0.59 |
| ASA | 2.12 | 0.6–7.43 | 0.23 |
| Injection < 6 months | 3.46 | 0.79–15 | 0.09 |
CI: Confidence interval; BMI: Body mass index; ASA: American society of anesthesiologists.
Comparison between males and females.
| Characteristics | Males | Females |
|
|---|---|---|---|
| Mean age, years ± SD | 70.5 ± 8.8 | 72.3 ± 8.9 | 0.12 a |
| Mean BMI, kg/m2 ± SD | 30.6 ± 5.2 | 30.9 ± 5.4 | 0.71 a |
| Smoking (Active or cessation), | 35 | 28 | 0.001 b |
| Diabetes mellitus, | 21 | 29 | 0.01 b |
| Active alcoholism, | 19 | 4 | 0.0001 b |
| ASA ≥ 3, | 37 | 60 | 0.01 b |
| Injection < 6 months, | 12 | 30 | 0.88 b |
at-test; b χ2 -test. SD: Standard-deviation; BMI: Body mass index; ASA: American society of anesthesiologists.